European shares surged on Friday, driven by renewed hopes for a Middle East diplomatic breakthrough that lowered oil prices. The pan-Europe...

India's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...

The benchmark snapped a four-day losing streak on Thursday, as ⁠investors digested the European Central Bank's rate hike and largely looked...

Britain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatme...

Lilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients with obesity...

The S&P 500 and Nasdaq hit record closing highs as hopes of a US Iran ceasefire extension boosted sentiment. Investors also digested US inf...

Eli Lilly raised its annual profit and revenue forecasts and posted better-than-expected first quarter on Thursday, on steady demand for it...

Foundayo Eli Lilly weight loss pill: Eli Lilly drug, orforglipron, which will be sold under the brand name Foundayo, is a once-daily oral m...

The US FDA has approved Eli Lilly's new weight-loss pill, Foundayo. This marks a significant step in the ongoing competition with rival Nov...

The pill was approved by the US Food and Drug Administration last month, a boon to Novo Nordisk as it looks to regain ground lost to U.S. r...

Eli Lilly's experimental weight loss pill, orforglipron, demonstrated an average weight loss of 12% in a late-stage trial, falling short of...

Eli Lilly has commenced phase three clinical trials in India for a new oral weight-loss drug called orforglipron. The trials aim to assess ...

Researchers found that a combination of extracts taken from cannabis and vitamin A shows promise as a drug to tackle obesity.